Compare EDAP & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDAP | ELDN |
|---|---|---|
| Founded | 1979 | 2004 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.6M | 123.1M |
| IPO Year | 1997 | N/A |
| Metric | EDAP | ELDN |
|---|---|---|
| Price | $4.13 | $2.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $8.50 | $8.50 |
| AVG Volume (30 Days) | 76.0K | ★ 794.2K |
| Earning Date | 11-06-2025 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $74,853,925.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.61 | N/A |
| 52 Week Low | $1.21 | $1.35 |
| 52 Week High | $4.29 | $4.97 |
| Indicator | EDAP | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 66.29 | 61.33 |
| Support Level | $3.44 | $2.09 |
| Resistance Level | $4.28 | $2.27 |
| Average True Range (ATR) | 0.35 | 0.13 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 83.19 | 75.42 |
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.